Clinical Research & Patient Care Core (CRPCC)
临床研究
基本信息
- 批准号:10431471
- 负责人:
- 金额:$ 19.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-03-10 至 2027-02-28
- 项目状态:未结题
- 来源:
- 关键词:AddressAmbulatory Care FacilitiesBiomedical ResearchCaringCause of DeathChestCitiesClinicClinicalClinical ManagementClinical ResearchClinical ServicesCollectionCommunicable DiseasesCommunicationCommunitiesComplexConsultationsCountryCustomDataData AnalysesDevelopmentDiabetes MellitusDisciplineEducationEducational CurriculumEnrollmentEpidemiologyEthicsEvaluationExtreme drug resistant tuberculosisField WorkersFoundationsFundingFunding AgencyFutureHealthHealth ProfessionalHomelessnessHospitalsHuman Subject ResearchHybridsIncidenceInfrastructureInpatientsInstitutesInstitutionKnowledgeLaboratoriesLeadershipLearningLength of StayLogisticsMedicalMentorsMexicanMexicoMissionMultidrug-Resistant TuberculosisNon-Insulin-Dependent Diabetes MellitusOralOutpatientsParticipantPathogenesisPatient CarePatientsPersonsPhysiciansPilot ProjectsPopulationPrevention strategyQualitative EvaluationsQuantitative EvaluationsResearchResearch DesignResearch InstituteResearch PersonnelResearch TrainingResourcesRotationScienceSideSiteSocial ProblemsSouth TexasSpecimenSpecimen HandlingStructureTexasThoracic RadiographyTrainingTreatment outcomeTuberculosisUniversitiesVaccinesWorkbiocontainment facilityclinical careclinical centerclinical research sitecomorbiditycritical periodcurriculum enhancementdesigndiagnostic strategyexperiencefield studyhuman old age (65+)improvedinterdisciplinary approachinterdisciplinary curriculuminterestlaboratory experimentmembermetropolitanmultidisciplinarynext generationpeerpreventprogramsprospectiveresearch studyskillssocialsuccesstherapy adverse effecttooltransmission processtreatment strategytuberculosis diagnosticstuberculosis treatmentvirtual
项目摘要
IN-TRAC Clinical Research & Patient Care Core (CRPCC) ABSTRACT
Tuberculosis (TB) is a leading infectious disease cause of death worldwide. In the US, TB incidence rates are
historically low, but control remains challenging in certain populations, including the communities along the US
border with Mexico. Thus, there is an urgent need for the next generation of TB researchers to have an
understanding of the clinical and epidemiological aspects of TB research, as a foundation for their future
leadership in the development of improved TB diagnostics, surveillance, treatments and vaccines. The Clinical
Research & Patient Care Core (CRPCC) of the IN-TRAC will provide to New TB Investigators (NIs) and
investigators new to the TB field, the infrastructure, resources and training in TB clinical research, and education
on the challenges faced by clinicians in managing TB cases. Our training sites are strategically located in south
Texas, a state adjacent to Mexico, which is the number one country of origin for foreign-born TB cases in the
US. The TB clinical research site is led by Dr. Restrepo, an expert in TB field epidemiology and pathogenesis in
TB patients with diabetes comorbidity or old age. Her field site is unique within the US due to its access to TB
patients enrolled on the Mexican side of the Texas border. The TB patient care training will be in San Antonio,
led by Drs. Armitige and Seaworth, an exemplary team of physicians who are affiliated with the only free-standing
TB hospital in the US, the Texas Center for Infectious Diseases (TCID). In the same setting, there are also busy
outpatient clinics: The San Antonio Metropolitan Health Department Chest Clinic, and a TB regional training and
medical consultation Center of Excellence (The Heartland National TB Center; HNTBC). Our Aims are to: Aim
1. Execute a personalized training curriculum on TB clinical research studies. We have designed a hybrid
(hands-on and virtual) training curriculum for IN-TRAC participants on all aspects of Clinical TB Research,
including ethics, study design, field logistics, data and specimen management, specimen processing and data
analysis plans and communications. Aim 2. Execute a personalized training curriculum on TB patient care.
IN-TRAC participants will be educated on the complex set of decisions that physicians make, particularly during
the management of difficult TB cases (e.g. with DR-TB, or with social problems such as homelessness), and
who require specialized management and prolonged in-hospital stays.
The mentoring team will meet with each IN-TRAC participant prior to their rotation to discuss customization of
the core curriculum, including the development of a pilot project, depending on the IN-TRAC participant’s interest.
IN-TRAC participants will provide a written and oral evaluation of their training experience.
IN-TRAC临床研究与病人护理核心(CRPCC)摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Larry S. Schlesinger其他文献
Mycobacterium tuberculosis remodels host transcriptome
结核分枝杆菌重塑宿主转录组
- DOI:
10.1038/s41564-021-01056-x - 发表时间:
2022-01-31 - 期刊:
- 影响因子:19.400
- 作者:
Melanie A. Carless;Larry S. Schlesinger - 通讯作者:
Larry S. Schlesinger
Identifying Mycobacterium tuberculosis virulence determinants - new technologies for a difficult problem.
识别结核分枝杆菌毒力决定因素——解决难题的新技术。
- DOI:
- 发表时间:
2000 - 期刊:
- 影响因子:15.9
- 作者:
Lucy E. Desjardin;Larry S. Schlesinger - 通讯作者:
Larry S. Schlesinger
Antibody-independent classical complement pathway activation by wildtype and LPS O-antigen mutant <em>Francisella tularensis</em> strains
- DOI:
10.1016/j.molimm.2010.05.146 - 发表时间:
2010-08-01 - 期刊:
- 影响因子:
- 作者:
Corey D. Clay;John S. Gunn;Larry S. Schlesinger - 通讯作者:
Larry S. Schlesinger
Timing matters in macrophage/CD4+ T cell interactions: an agent-based model comparing emMycobacterium tuberculosis/em host-pathogen interactions between latently infected and naïve individuals
时机在巨噬细胞/CD4+T 细胞相互作用中很重要:一个基于代理的模型比较了潜伏感染和未感染个体之间的结核分枝杆菌宿主-病原体相互作用
- DOI:
10.1128/msystems.01290-24 - 发表时间:
2025-02-27 - 期刊:
- 影响因子:4.600
- 作者:
Alexis Hoerter;Alexa Petrucciani;Jordan Bonifacio;Eusondia Arnett;Larry S. Schlesinger;Elsje Pienaar - 通讯作者:
Elsje Pienaar
Impact of the elderly lung mucosa on emMycobacterium tuberculosis/em transcriptional adaptation during infection of alveolar epithelial cells
老年肺黏膜对肺泡上皮细胞感染期间结核分枝杆菌转录适应性的影响
- DOI:
10.1128/spectrum.01790-24 - 发表时间:
2024-10-30 - 期刊:
- 影响因子:3.800
- 作者:
Angélica M. Olmo-Fontánez;Anna Allué-Guardia;Andreu Garcia-Vilanova;Jeremy Glenn;Shu-Hua Wang;Robert E. Merritt;Larry S. Schlesinger;Joanne Turner;Yufeng Wang;Jordi B. Torrelles - 通讯作者:
Jordi B. Torrelles
Larry S. Schlesinger的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Larry S. Schlesinger', 18)}}的其他基金
Interdisciplinary NexGen TB research Advancement Center (IN-TRAC)
跨学科 NexGen 结核病研究推进中心 (IN-TRAC)
- 批准号:
10588203 - 财政年份:2022
- 资助金额:
$ 19.99万 - 项目类别:
Interdisciplinary NexGen TB research Advancement Center (IN-TRAC)
跨学科 NexGen 结核病研究推进中心 (IN-TRAC)
- 批准号:
10431465 - 财政年份:2022
- 资助金额:
$ 19.99万 - 项目类别:
Macrophage nuclear receptors, metabolism and immune effectors during health and M. tuberculosis infection
健康和结核分枝杆菌感染期间的巨噬细胞核受体、代谢和免疫效应器
- 批准号:
10450960 - 财政年份:2020
- 资助金额:
$ 19.99万 - 项目类别:
Macrophage nuclear receptors, metabolism and immune effectors during health and M. tuberculosis infection
健康和结核分枝杆菌感染期间的巨噬细胞核受体、代谢和免疫效应器
- 批准号:
10457308 - 财政年份:2019
- 资助金额:
$ 19.99万 - 项目类别:
Macrophage nuclear receptors, metabolism and immune effectors during health and M. tuberculosis infection- Diversity Supplement
健康和结核分枝杆菌感染期间的巨噬细胞核受体、代谢和免疫效应器 - Diversity Supplement
- 批准号:
10116937 - 财政年份:2019
- 资助金额:
$ 19.99万 - 项目类别:
Expansion of Marmoset Breeding Facilities to Meet Increasing Research Demands
扩建狨猴饲养设施以满足不断增长的研究需求
- 批准号:
9933536 - 财政年份:2019
- 资助金额:
$ 19.99万 - 项目类别:
Macrophage nuclear receptors, metabolism and immune effectors during health and M. tuberculosis infection
健康和结核分枝杆菌感染期间的巨噬细胞核受体、代谢和免疫效应器
- 批准号:
10215474 - 财政年份:2019
- 资助金额:
$ 19.99万 - 项目类别: